PDCD1 and metastatic melanoma: In a phase I clinical study, involving 142 patients with metastatic melanoma, the objective-response rate and progression-free survival have been found significantly higher with ipilimumab (CTLA-4 inhibitor) and nivolumab (PD-1 inhibitor) combined therapy than ipilimumab monotherapy (121).